IMMUNO-ONCOLOGY INSIGHTS

Enhancing preclinical predictivity

Guest Editor:
Christian Schmees at University of Tuebingen
Christian Schmees
at University of Tuebingen
Christian Schmees is heading the Tumor Biology group at the Natural and Medical Sciences Institute (NMI) at the University of Tuebingen, Germany. He received his undergraduate degree in biochemistry from Tuebingen University in 2002. Since 2006 he holds a PhD (with highest honors) in cancer immunology from the Technical University of Munich, Germany. His thesis resulted in the identification of gamma-glutamyl-transpeptidase as the major factor for T cell specific immune evasion of the tumorigenic bacterium Helicobacter pylori. As a post-doc he joined the laboratories of Carl-Henrik Heldin at the Ludwig Institute for Cancer Research (LICR) in Uppsala, Sweden (2006-2010) and Philippe Bastiaens at the Max-Planck Institute of Molecular Physiology in Dortmund, Germany (2010-2011). He received fellowships from the German Research Foundation and the LICR to support his research on differential regulation of intracellular PDGF α- and β-receptor trafficking in cancer cells. In 2011 he joined the Natural and Medical Sciences Institute at the University of Tuebingen (NMI) as a senior scientist in tumor biology and was appointed Head of Tumor Biology in 2014. Ongoing projects in his group are focusing on the development of clinically relevant cellular model systems for drug development and target validation in translational oncology. These approaches are combined with gene editing and silencing technologies as well as protein profiling and immunophenotyping platforms for mode-of-action analyses of different compound classes. Dr. Schmees is member of the Association for Cancer Immunotherapy (CIMT).

Translational R&D insights for the allogeneic CAR T cell...

B Sasu
Barbra Sasu
Chief Scientific Officer, Allogene
Barbra Sasu, PhD, is the Chief Scientific Officer of Allogene. Barbra joined Allogene as Chief Scientific Officer in April 2018 when the company acquired the allogeneic cell therapy assets from Pfizer. Barbra received a PhD from the Paterson Institute for Cancer Research in Manchester, UK, in the laboratory of T. Michael Dexter, FRS. She conducted postdoctoral research at Harvard Medical School in the laboratory of T. Keith Blackwell, MD, PhD.  Barbra joined Amgen in 2001 to work on normal and malignant hematology initially and later expanded her focus to include immune-oncology with an emphasis on T-cell redirective therapies, specifically BiTE molecules. In 2013, she joined Pfizer to become involved with large molecule immuno-oncology including the Pfizer T-cell redirection programs and led diligence to look for a CAR T collaboration partner. This collaboration search resulted in the Cellectis partnership in 2014 and the collaboration with Servier for clinical execution of UCART19 and other preclinical assets.
5 August 2021
Interview

Enhancing preclinical predictivity: what is going wrong...

C Schmees
Christian Schmees, PhD
Head of Tumor Biology, NMI Natural and Medical Sciences Institute at the University of Tuebingen, Germany
Christian Schmees is heading the Tumor Biology group at the Natural and Medical Sciences Institute (NMI) at the University of Tuebingen, Germany. He received his undergraduate degree in biochemistry from Tuebingen University in 2002. Since 2006 he holds a PhD (with highest honors) in cancer immunology from the Technical University of Munich, Germany. His thesis resulted in the identification of gamma-glutamyl-transpeptidase as the major factor for T cell specific immune evasion of the tumorigenic bacterium Helicobacter pylori. As a post-doc he joined the laboratories of Carl-Henrik Heldin at the Ludwig Institute for Cancer Research (LICR) in Uppsala, Sweden (2006-2010) and Philippe Bastiaens at the Max-Planck Institute of Molecular Physiology in Dortmund, Germany (2010-2011). He received fellowships from the German Research Foundation and the LICR to support his research on differential regulation of intracellular PDGF α- and β-receptor trafficking in cancer cells. In 2011 he joined the Natural and Medical Sciences Institute at the University of Tuebingen (NMI) as a senior scientist in tumor biology and was appointed Head of Tumor Biology in 2014. Ongoing projects in his group are focusing on the development of clinically relevant cellular model systems for drug development and target validation in translational oncology. These approaches are combined with gene editing and silencing technologies as well as protein profiling and immunophenotyping platforms for mode-of-action analyses of different compound classes. Dr. Schmees is member of the Association for Cancer Immunotherapy (CIMT).
5 August 2021
Foreword

Microphysiological systems for immuno-oncology: opportunities...

L Low
Lucie A Low
National Center for Advancing Translational Sciences, National Institutes of Health, 6701 Democracy Blvd, 9th Floor, Bethesda, MD 20892, USA lucie.low@nih.gov
Lucie Low is the scientific program manager of the trans-NIH Tissue Chip for Drug Screening program at the National Center for Advancing Translational Sciences (NCATS). She also serves as the NIH-NASA liaison point of contact, facilitating collaborations between NIH and NASA on areas of overlapping agency interest. Prior to joining NCATS in 2016, Low was an intramural research fellow at the National Center for Complementary and Integrative Health (NCCIH), researching the complex interactions between pain, emotion and cognition. She obtained her undergraduate degree from Magdalen College, Oxford University, and her Masters and PhD degrees in Neuroscience from University College London in the UK. She undertook postdoctoral training at McGill University in Montreal, Canada, before joining the US National Institutes of Health in 2012. She has authored over 20 peer-reviewed manuscripts on the neuroscience of pain and tissue chips.
5 August 2021
Editorial

Advancement of precision oncology by integration of highly...

M Pawlak,
Michael Pawlak
Natural and Medical Sciences Institute at the University of Tuebingen, Reutlingen, Germany and Natural and Medical Sciences Institute Technologietransfer GmbH, Reutlingen, Germany
M Templin,
Markus Templin
Natural and Medical Sciences Institute at the University of Tuebingen, Reutlingen, Germany
C Schmees
Christian Schmees
Natural and Medical Sciences Institute at the University of Tuebingen, Reutlingen, Germany
Christian Schmees is heading the Tumor Biology group at the Natural and Medical Sciences Institute (NMI) at the University of Tuebingen, Germany. He received his undergraduate degree in biochemistry from Tuebingen University in 2002. Since 2006 he holds a PhD (with highest honors) in cancer immunology from the Technical University of Munich, Germany. His thesis resulted in the identification of gamma-glutamyl-transpeptidase as the major factor for T cell specific immune evasion of the tumorigenic bacterium Helicobacter pylori. As a post-doc he joined the laboratories of Carl-Henrik Heldin at the Ludwig Institute for Cancer Research (LICR) in Uppsala, Sweden (2006-2010) and Philippe Bastiaens at the Max-Planck Institute of Molecular Physiology in Dortmund, Germany (2010-2011). He received fellowships from the German Research Foundation and the LICR to support his research on differential regulation of intracellular PDGF α- and β-receptor trafficking in cancer cells. In 2011 he joined the Natural and Medical Sciences Institute at the University of Tuebingen (NMI) as a senior scientist in tumor biology and was appointed Head of Tumor Biology in 2014. Ongoing projects in his group are focusing on the development of clinically relevant cellular model systems for drug development and target validation in translational oncology. These approaches are combined with gene editing and silencing technologies as well as protein profiling and immunophenotyping platforms for mode-of-action analyses of different compound classes. Dr. Schmees is member of the Association for Cancer Immunotherapy (CIMT).
5 August 2021
Expert Insight

Recent evolution in the bispecific antibody and engineered...

R Clynes
Raphael Clynes
Vice President of Translational Biology, Xencor
Raphael Clynes, MD, PhD, Vice President of Translational Biology, Xencor. Dr. Clynes is a medical oncologist/hematolo-gist and a cellular immunologist with more than 100 publications in cancer and autoimmunity. Prior to joining Xencor in 2017, Dr. Clynes evaluated combination immunotherapies in Early Clinical Development at Bristol Myers Squibb. Prior to moving to industry in 2014, Dr. Clynes led NIH-funded research programs over two decades in cancer and autoimmunity at The Rockefeller University, MSKCC and Columbia University.
5 August 2021
Interview

Enhancing preclinical predictivity in I-O: what is going...

P Ellmark,
Peter Ellmark
Chief Scientific Officer, Alligator Bioscience
Peter Ellmark joined Alligator Bioscience in 2008 and is Chief scientific officer since 2021. He holds a PhD and an associate professorship in Immunotechnology at Lund University and has more than 20 years’ experience of developing antibodies for immunotherapy of cancer. Dr. Ellmark´s research interest is focused on developing mono- and bispecific antibodies, in particular CD40 targeting therapies, for tumor directed immunotherapy of cancer.
D Gilham,
David Gilham
Chief Scientific Officer, Celyad Oncology
M Steegmaier et al.
Martin Steegmaier
Head of Research, MorphoSys
5 August 2021
Expert Roundtable
  • Gain deeper insights into the mechanisms of immune cell killing of tumor...

    C Souders,
    T Dale,
    N Bevan et al.
    Colby Souders
    Colby Souders
    Chief Scientific Officer at Abveris
    Tim  Dale
    Tim Dale
    Head of BioAnalytics Applications at Sartorius
    Nicola Bevan
    Nicola Bevan
    Manager of Cell Imaging Applications at Sartorius
    Jeffrey Skolnik
    Jeffrey Skolnik
    Senior Vice President, Clinical Development at Inovio Pharmaceuticals, Inc
    6 Oct 2021
    8
    Days
    0
    Hrs
    18
    Min
    Register
  • The therapeutic gene editing solution – cell therapy for solid tumors

    B Sasu,
    P Sivakumar,
    J Trager et al.
    Barbra Sasu
    Barbra Sasu
    Chief Scientific Officer at Allogene Therapeutics, Inc
    Pallavur Sivakumar
    Pallavur Sivakumar
    Scientific Vice President and Head of Discovery Immuno-Oncology and Cell Therapy Thematic Research Center at Bristol Myers Squibb
    James Trager
    James Trager
    Chief Scientific Officer at Nkarta Therapeutics, Inc
    Jennifer Harbottle
    Jennifer Harbottle
    Senior Scientist, R&D, Cell and Gene Therapy at Horizon Discovery
    30 Sep 2021
    2
    Days
    0
    Hrs
    18
    Min
    Register
  • Get your non-viral T cell engineering process ready for clinical manufacturing

    M Rietenbach,
    S Wild,
    K Patel
    Melanie Rietenbach
    Melanie Rietenbach
    Global Product Manager at Miltenyi Biotec
    Stefan Wild
    Stefan Wild
    Senior Manager Research and Development at Miltenyi Biotec
    Kunal Patel
    Kunal Patel
    Process engineering manager at Miltenyi Biotec
    21 September 2021
    Watch now
  • Cell-based therapies for cancer treatment: leveraging advanced flow cytometry...

    N Senutovitch,
    R Fan,
    T Laskowski
    Nina Senutovitch
    Nina Senutovitch
    Senior Scientist, Cell Analytics Development at Sartorius
    Rong Fan
    Rong Fan
    Professor of Biomedical Engineering at Yale University
    Tamara Laskowski
    Tamara Laskowski
    Scientific Project Director at MD Anderson Cancer Center
    5 August 2021
    Watch now
  • Accelerating CAR-T process development: The power of process insight

    J Hupfeld
    Julia Hupfeld
    Julia Hupfeld
    Solution Marketing Manager at Sartorius
    29 July 2021
    Watch now
  • Applying a closed, modular, semi-automated system to CAR T cell therapy manufacturing

    Y Ji,
    S Ensari, PhD,
    N Moore
    Yongchang Ji
    Yongchang Ji
    Scientist II, Cell Transfection Group at Thermo Fisher Scientific
    Semsi Ensari, PhD
    Semsi Ensari, PhD
    Senior Director at Kite Pharma, Inc
    Nathan Moore
    Nathan Moore
    Associate Director, Engineering & Automation Cell Therapies, Pharmaceutical Sciences at Takeda Pharmaceutical Company Limited
    29 June 2021
    Watch now
  • Overcoming purification challenges in antibody therapeutics manufacturing with...

    L Sierkstra
    Laurens  Sierkstra
    Laurens Sierkstra
    Senior Director, Business Leader, Purification at Thermo Fisher Scientific
    10 June 2021
    Watch now
  • Protein biomarkers in plasma: revealing biological insights into the tumor...

    G Boland,
    A Mehta
    Genevieve  Boland
    Genevieve Boland
    Surgical Oncologist at Massachusetts General Hospital
    Arnav  Mehta
    Arnav Mehta
    Postdoctoral Researcher at Broad Institute of MIT and Harvard
    20 May 2021
    Watch now
  • Latest content

    Gain deeper insights into the mechanisms of immune cell killing of tumor...

    C Souders,
    T Dale,
    N Bevan et al.
    Dr Colby Souders
    Dr Colby Souders
    Chief Scientific Officer, Abveris
    Tim Dale, PhD
    Tim Dale, PhD
    Head of BioAnalytics Applications, Sartorius
    Nicola Bevan
    Nicola Bevan
    Manager of Cell Imaging Applications, Sartorius
     Jeffrey Skolnik, M.D.
    Jeffrey Skolnik, M.D.
    Senior Vice President, Clinical Development, Inovio
    6 Oct 2021
    8
    Days
    0
    Hrs
    18
    Min
    Register

    Get your non-viral T cell engineering process ready for clinical manufacturing

    M Rietenbach,
    S Wild,
    K Patel
    Melanie Rietenbach
    Melanie Rietenbach
    Global Product Manager Miltenyi Biotec
    Stefan Wild
    Stefan Wild
    Senior Manager, Research and Development, Miltenyi Biotec
    Kunal Patel
    Kunal Patel
    Process Engineering Manager, Miltenyi Biotec
    21 September 2021
    Watch now